Extended Transgene Expression from a Nonintegrating Adenoviral Vector Containing Retroviral Elements

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2008 Apr 5

PMID 18388914

Citations 22

Authors

Changyu Zheng

Joseph M Vitolo

Weitian Zhang

Fumi Mineshiba

John A Chiorini

Bruce J Baum

Affiliations

Soon will be listed here.

Abstract

We studied the effects of specific retroviral elements in a first-generation serotype 5 adenoviral (Ad5) vector, AdLTR(2)EF1alpha-hEPO. This vector contains 858 base pair (bp) [251-bp envelope sequence plus 607-bp long-terminal repeat (LTR)] from Moloney murine leukemia virus (MoMLV), upstream of the human elongation factor-1alpha (EF1alpha) promoter and human erythropoietin (hEPO) cDNA, with the LTR sequence downstream of the polyadenylation signal. We compared expression of AdLTR(2)EF1alpha-hEPO with corresponding expressions of two conventional Ad5 vectors, AdEF1alpha-hEPO and AdCMV-hEPO, in vivo in submandibular glands in rats. Both the conventional vectors yielded low serum hEPO levels by day 7, and little change in hematocrits. In contrast, after receiving AdLTR(2)EF1alpha-hEPO, the rats showed elevated hEPO levels and hematocrits for 1-3 months. In vitro studies showed that the integration efficiencies of all the vectors were similar (approximately 10(-3)). Approximately 0.1% of the vector genomes were present 1 year after delivery in the case of each of the three vectors, primarily as intact linear double-strand DNA. The unique results seen with AdLTR(2)EF1alpha-hEPO are partly because of LTR enhancer activity. However, other cis-acting activity, which is not immunomodulatory but nevertheless influences promoter methylation, appears to be involved. A vector such as AdLTR(2)EF1alpha-hEPO may prove useful in clinical applications in which extended, but not "permanent," transgene expression is desirable.

Citing Articles

Gene Therapeutic Delivery to the Salivary Glands.

Upadhyay A, Cao U, Hariharan A, Almansoori A, Tran S Adv Exp Med Biol. 2023; 1436:55-68.

PMID: 36826746 DOI: 10.1007/5584_2023_766.

Adenovirus vectors in hematopoietic stem cell genome editing.

Li C, Lieber A FEBS Lett. 2019; 593(24):3623-3648.

PMID: 31705806 PMC: 10473235. DOI: 10.1002/1873-3468.13668.

Neurturin Gene Therapy Protects Parasympathetic Function to Prevent Irradiation-Induced Murine Salivary Gland Hypofunction.

Ferreira J, Zheng C, Lombaert I, Goldsmith C, Cotrim A, Symonds J Mol Ther Methods Clin Dev. 2018; 9:172-180.

PMID: 29560384 PMC: 5857485. DOI: 10.1016/j.omtm.2018.02.008.

Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction.

Alevizos I, Zheng C, Cotrim A, Liu S, McCullagh L, Billings M Gene Ther. 2016; 24(3):176-186.

PMID: 27996967 PMC: 5373995. DOI: 10.1038/gt.2016.87.

Inhibition of autophagy by 3-MA enhances IL-24-induced apoptosis in human oral squamous cell carcinoma cells.

Li J, Yang D, Wang W, Piao S, Zhou J, Saiyin W J Exp Clin Cancer Res. 2015; 34:97.

PMID: 26361755 PMC: 4567787. DOI: 10.1186/s13046-015-0211-0.

References

Zirger J, Liu C, Barcia C, Castro M, Lowenstein P . Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors. Viral Immunol. 2006; 19(3):508-17. PMC: 1847585. DOI: 10.1089/vim.2006.19.508. View

Michel M, Hirt B, Weil R . Mouse cellular DNA enclosed in polyoma viral capsids (pseudovirions). Proc Natl Acad Sci U S A. 1967; 58(4):1381-8. PMC: 223935. DOI: 10.1073/pnas.58.4.1381. View

Zheng C, Baum B . Long-term expression after infection by the hybrid vector AdLTR-luc is from integrated transgene. Biochem Biophys Res Commun. 2002; 291(1):34-40. DOI: 10.1006/bbrc.2002.6401. View

Guo H, Seixas-Silva Jr J, Epperly M, Gretton J, Shin D, Bar-Sagi D . Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res. 2003; 159(3):361-70. DOI: 10.1667/0033-7587(2003)159[0361:porioc]2.0.co;2. View

Voutetakis A, Bossis I, Kok M, Zhang W, Wang J, Cotrim A . Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J Endocrinol. 2005; 185(3):363-72. DOI: 10.1677/joe.1.06171. View

Redman R . Proliferative activity by cell type in the developing rat parotid gland. Anat Rec. 1995; 241(4):529-40. DOI: 10.1002/ar.1092410411. View

Borges L, Rex K, Chen J, Wei P, Kaufman S, Scully S . A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. Int J Radiat Oncol Biol Phys. 2006; 66(1):254-62. DOI: 10.1016/j.ijrobp.2006.05.025. View

Zheng C, Wang J, Baum B . Integration efficiency of a hybrid adenoretroviral vector. Biochem Biophys Res Commun. 2002; 300(1):115-20. DOI: 10.1016/s0006-291x(02)02801-2. View

Baum B, Wellner R, Zheng C . Gene transfer to salivary glands. Int Rev Cytol. 2002; 213:93-146. DOI: 10.1016/s0074-7696(02)13013-0. View

10.

Shirasuna K, Sato M, Miyazaki T . A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer. 1981; 48(3):745-52. DOI: 10.1002/1097-0142(19810801)48:3<745::aid-cncr2820480314>3.0.co;2-7. View

11.

Sprangers M, Lakhai W, Koudstaal W, Verhoeven M, Koel B, Vogels R . Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMC: 262545. DOI: 10.1128/JCM.41.11.5046-5052.2003. View

12.

Jooss K, Chirmule N . Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 2003; 10(11):955-63. DOI: 10.1038/sj.gt.3302037. View

13.

Kagami H, Atkinson J, Michalek S, Handelman B, Yu S, Baum B . Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of oral tolerance. Hum Gene Ther. 1998; 9(3):305-13. DOI: 10.1089/hum.1998.9.3-305. View

14.

Zheng C, Baum B . Evaluation of viral and mammalian promoters for use in gene delivery to salivary glands. Mol Ther. 2005; 12(3):528-36. DOI: 10.1016/j.ymthe.2005.03.008. View

15.

Harui A, Suzuki S, Kochanek S, Mitani K . Frequency and stability of chromosomal integration of adenovirus vectors. J Virol. 1999; 73(7):6141-6. PMC: 112682. DOI: 10.1128/JVI.73.7.6141-6146.1999. View

16.

Amalfitano A, Chamberlain J . Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy. Gene Ther. 1997; 4(3):258-63. DOI: 10.1038/sj.gt.3300378. View

17.

Schaack J, Ho W, Freimuth P, Shenk T . Adenovirus terminal protein mediates both nuclear matrix association and efficient transcription of adenovirus DNA. Genes Dev. 1990; 4(7):1197-208. DOI: 10.1101/gad.4.7.1197. View

18.

Becker T, Noel R, Coats W, Gomez-Foix A, Alam T, Gerard R . Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994; 43 Pt A:161-89. DOI: 10.1016/s0091-679x(08)60603-2. View

19.

Harel J, Rassart E, Jolicoeur P . Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virology. 1981; 110(1):202-7. DOI: 10.1016/0042-6822(81)90022-2. View

20.

Marienfeld U, Haack A, Thalheimer P, Brackmann H, Poller W . 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes. Gene Ther. 1999; 6(6):1101-13. DOI: 10.1038/sj.gt.3300928. View